Skip to main content

Dihexa vs Pinealon

Both Dihexa and Pinealon are used for cognitive. Here's how their evidence, dosing, and regulatory status actually compare.

Dihexa

Evidence C

Dihexa (PNB-0408)

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

View full Dihexa profile →

Pinealon

Evidence C

Pinealon (EDR)

A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.

View full Pinealon profile →

Side-by-Side

AttributeDihexaPinealon
Evidence GradeCC
FDA StatusNot FDA-approved — research compound (HGF/c-Met-mimetic)Not FDA-approved — Russian-origin research peptide
Typical Dose8–45 mg orally daily (research-only)5–10 mg daily for 10–20 days (subcutaneous, cycled)
Clinics Indexed109
Categoriescognitive, neuroprotectioncognitive, longevity

Key reported benefits — Dihexa

  • Synaptogenesis (preclinical)
  • Memory improvement (animal)
  • Possible Alzheimer's relevance

Key reported benefits — Pinealon

  • Cognitive function (preclinical)
  • Reduced oxidative damage
  • Sleep/circadian effects

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons